drugset / Trial / NCT07013487
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
Timeline
- Start
- 2025-06-11
- Primary completion
- 2031-10-24
- Completion
- 2031-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | V181 | Vaccine | 0.5 ml | Subcutaneous |
Indications
No indication recorded.